前列腺特异性抗原（PSA）、PSA衍生物、游离前列腺特异性抗原（proPSA）及前列腺健康指数在前列腺癌诊断中的应用
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.
作者信息
Ayyıldız Sema Nur, Ayyıldız Ali
机构信息
Department of Biochemical, Ordu University Faculty of Medicine, Ordu, Turkey.
Department of Urology, Ordu University Faculty of Medicine, Ordu, Turkey.
出版信息
Turk J Urol. 2014 Jun;40(2):82-8. doi: 10.5152/tud.2014.94547.
Abstract
Currently, prostate- specific antigen (PSA) is the most common oncological marker used for prostate cancer screening. However, high levels of PSA in benign prostatic hyperplasia and prostatitis decrease the specificity of PSA as a cancer marker. To increase the specificity of PSA, PSA derivatives and PSA kinetics have been used. However, these new techniques were not able to increase the diagnostic specificity for prostate cancer. Therefore, the search for new molecules and derivatives of PSA continues. With the aim of increasing the specificity of prostate cancer diagnosis, proPSA and the Prostate Health Index have been introduced. In this review, the roles of PSA, PSA derivatives, proPSA and the Prostate Health Index in Prostate Cancer diagnosis are examined.
摘要
目前，前列腺特异性抗原（PSA）是用于前列腺癌筛查的最常见肿瘤标志物。然而，良性前列腺增生和前列腺炎中高水平的PSA降低了PSA作为癌症标志物的特异性。为了提高PSA的特异性，人们使用了PSA衍生物和PSA动力学。然而，这些新技术未能提高前列腺癌的诊断特异性。因此，对PSA新分子和衍生物的探索仍在继续。为了提高前列腺癌诊断的特异性，前列腺特异性抗原（proPSA）和前列腺健康指数已被引入。在本综述中，将探讨PSA、PSA衍生物、proPSA和前列腺健康指数在前列腺癌诊断中的作用。
相似文献
1
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.前列腺特异性抗原（PSA）、PSA衍生物、游离前列腺特异性抗原（proPSA）及前列腺健康指数在前列腺癌诊断中的应用
Turk J Urol. 2014 Jun;40(2):82-8. doi: 10.5152/tud.2014.94547.
2
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.在总前列腺特异性抗原范围为4.0至10.0 ng/ml的男性中，评估游离前列腺特异性抗原用于前列腺癌早期检测的情况。
J Urol. 2003 Sep;170(3):723-6. doi: 10.1097/01.ju.0000086940.10392.93.
3
[[-2] proPSA: A Novel Marker of Prostate Cancer].[-2]前列腺特异性抗原：前列腺癌的一种新型标志物
Rinsho Byori. 2015 Jan;63(1):84-93.
4
5
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.血清中前列腺特异性抗原的酶原形式可提高前列腺癌的检测率。
Clin Chem. 2004 Jun;50(6):1017-25. doi: 10.1373/clinchem.2003.026823. Epub 2004 Mar 30.
6
Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.游离前列腺特异性抗原：一种用于早期检测前列腺癌的更具癌症特异性的前列腺特异性抗原形式。
Keio J Med. 2003 Jun;52(2):86-91. doi: 10.2302/kjm.52.86.
7
Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.前列腺特异性抗原前体在前列腺癌诊断中的应用价值。
Anticancer Res. 2007 Jan-Feb;27(1B):607-10.
8
PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer.前列腺癌早期诊断中前列腺特异性抗原（PSA）异构体的速度
Anticancer Res. 2015 Jun;35(6):3567-70.
9
Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.对于总前列腺特异性抗原水平为2 - 10 ng/ml的患者，血清异构体[-2]前列腺特异性抗原衍生物的检测在前列腺癌诊断中显示出比磁共振成像更高的准确性。
Scand J Urol. 2017 Aug;51(4):251-257. doi: 10.1080/21681805.2017.1298155. Epub 2017 Mar 29.
10
[Evaluation of (-2)proPSA in combination with total PSA and free PSA for the early detection of prostate cancer].[评估（-2）前列腺特异性抗原联合总前列腺特异性抗原和游离前列腺特异性抗原用于前列腺癌早期检测的效果]
Ann Biol Clin (Paris). 2013 Sep-Oct;71(5):537-44. doi: 10.1684/abc.2013.0894.
引用本文的文献
1
Comparative Analysis of miRNA Expression 106a-5p and 375-3p and Proteins ERK1/2, p38, β-Catenin and E-Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia.前列腺癌和良性前列腺增生中miRNA 106a - 5p和375 - 3p以及蛋白质ERK1/2、p38、β - 连环蛋白和E - 钙黏蛋白的表达比较分析
J Cell Mol Med. 2025 Aug;29(16):e70695. doi: 10.1111/jcmm.70695.
2
Multiplexed quantitative proteomics in prostate cancer biomarker development.前列腺癌生物标志物开发中的多重定量蛋白质组学。
Adv Cancer Res. 2024;161:31-69. doi: 10.1016/bs.acr.2024.04.003. Epub 2024 Apr 25.
3
Clinical assessment of TGFB1 and HP Relative Gene Expression in the Peripheral Blood of Prostate Cancer Patients.前列腺癌患者外周血 TGFB1 和 HP 相对基因表达的临床评估。
Asian Pac J Cancer Prev. 2024 Feb 1;25(2):709-717. doi: 10.31557/APJCP.2024.25.2.709.
4
Machine learning-based prediction model and visual interpretation for prostate cancer.基于机器学习的前列腺癌预测模型与可视化解读
BMC Urol. 2023 Oct 14;23(1):164. doi: 10.1186/s12894-023-01316-4.
5
Comparison of Serum Gamma Glutamyl Transferase Levels between Prostate Cancer Patients and Their Healthy Peers.前列腺癌患者与其健康同龄人血清γ-谷氨酰转移酶水平的比较。
Iran J Public Health. 2023 Jul;52(7):1487-1494. doi: 10.18502/ijph.v52i7.13251.
6
Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy.Ki67与内分泌治疗后前列腺癌的表观扩散系数
Front Surg. 2023 Apr 5;10:1140883. doi: 10.3389/fsurg.2023.1140883. eCollection 2023.
7
The Role and Significance of Bioumoral Markers in Prostate Cancer.生物标志物在前列腺癌中的作用及意义
Cancers (Basel). 2021 Nov 25;13(23):5932. doi: 10.3390/cancers13235932.
8
Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine.前列腺癌精准医学中的组织和液体生物标志物
J Pers Med. 2021 Jul 15;11(7):664. doi: 10.3390/jpm11070664.
9
Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.前列腺癌患者诊断、预后及治疗反应的血液源性生物标志物
J Pers Med. 2021 Apr 13;11(4):296. doi: 10.3390/jpm11040296.
10
Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.总前列腺特异性抗原和游离前列腺特异性抗原免疫测定之间的系统差异：使用帕辛和巴布洛克回归法进行比较
Indian J Clin Biochem. 2021 Apr;36(2):151-158. doi: 10.1007/s12291-019-0818-6. Epub 2019 Feb 13.
本文引用的文献
1
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study.血清同工型 [-2]前列腺特异性抗原衍生物在总 PSA 范围为 2-10ng/ml 时显著改善了初始活检前列腺癌的预测：一项多中心欧洲研究。
Eur Urol. 2013 Jun;63(6):986-94. doi: 10.1016/j.eururo.2013.01.011. Epub 2013 Jan 24.
2
Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis.游离前列腺特异性抗原 2 检测和前列腺健康指数（phi）在前列腺癌诊断中的应用：系统评价和荟萃分析。
Clin Chem Lab Med. 2013 Apr;51(4):729-39. doi: 10.1515/cclm-2012-0410.
3
Radical prostatectomy versus observation for localized prostate cancer.根治性前列腺切除术与观察等待治疗局限性前列腺癌的比较。
N Engl J Med. 2012 Jul 19;367(3):203-13. doi: 10.1056/NEJMoa1113162.
4
Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.术前前列腺特异性抗原同工型 p2PSA 及其衍生物 %p2PSA 和前列腺健康指数可预测行前列腺癌根治术患者的病理结局。
Eur Urol. 2012 Mar;61(3):455-66. doi: 10.1016/j.eururo.2011.10.038. Epub 2011 Nov 4.
5
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.一项关于 [-2] 前列腺特异性抗原联合前列腺特异性抗原和游离前列腺特异性抗原在前列腺特异性抗原 2.0 至 10.0ng/ml 范围内用于前列腺癌检测的多中心研究。
J Urol. 2011 May;185(5):1650-5. doi: 10.1016/j.juro.2010.12.032. Epub 2011 Mar 17.
6
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.ProPSA 与诊断性活检组织 DNA 含量相结合可提高预测主动监测计划中男性前列腺癌治疗需求的准确性。
Urology. 2011 Mar;77(3):763.e1-6. doi: 10.1016/j.urology.2010.07.526. Epub 2011 Jan 8.
7
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.EAU 前列腺癌指南。第 1 部分：局限性疾病的筛查、诊断和治疗。
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
8
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.一项前瞻性、多中心、美国国家癌症研究所早期检测研究网络的 [-2]proPSA 研究：提高前列腺癌的检出率并与癌症侵袭性相关。
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-200. doi: 10.1158/1055-9965.EPI-10-0007.
9
[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.在一项前瞻性前列腺癌筛查研究中，与总前列腺特异性抗原和游离前列腺特异性抗原相比，前激肽释放酶前列腺特异性抗原在区分前列腺癌与良性疾病方面更准确。
J Urol. 2010 Apr;183(4):1355-9. doi: 10.1016/j.juro.2009.12.056. Epub 2010 Feb 19.
10
Prostate specific antigen best practice statement: 2009 update.前列腺特异性抗原最佳实践声明：2009年更新版
J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.
Zotero 插件